<code id='E01AA88638'></code><style id='E01AA88638'></style>
    • <acronym id='E01AA88638'></acronym>
      <center id='E01AA88638'><center id='E01AA88638'><tfoot id='E01AA88638'></tfoot></center><abbr id='E01AA88638'><dir id='E01AA88638'><tfoot id='E01AA88638'></tfoot><noframes id='E01AA88638'>

    • <optgroup id='E01AA88638'><strike id='E01AA88638'><sup id='E01AA88638'></sup></strike><code id='E01AA88638'></code></optgroup>
        1. <b id='E01AA88638'><label id='E01AA88638'><select id='E01AA88638'><dt id='E01AA88638'><span id='E01AA88638'></span></dt></select></label></b><u id='E01AA88638'></u>
          <i id='E01AA88638'><strike id='E01AA88638'><tt id='E01AA88638'><pre id='E01AA88638'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:explore    Page View:4892
          Senate Finance Committee Chair Ron Wyden (D-Ore.) Leah Millis/Pool via AP

          WASHINGTON — Senators on the Finance Committee on Wednesday nearly unanimously passed a bill to clamp down on drug middlemen, but kicked the can down the road on some of the more challenging policies.

          The bill would offer some more transparency into the business practices of pharmacy benefit managers, ensure PBMs aren’t skimming off of the money they send to insurers, prohibit them from overcharging insurers, and ensure certain fees in the Medicare program aren’t tied to a drug’s price.

          advertisement

          “It’s pretty hard to get 26 votes around here,” Finance Chair Ron Wyden (D-Ore.) said after the vote. “So we’re thrilled.”

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          Merus drug and Keytruda shrank tumors in patients with head and neck cancer
          Merus drug and Keytruda shrank tumors in patients with head and neck cancer

          ThisimmunofluorescenceimageshowsTcells(ingreenandyellow)inthemicroenvironmentofaheadandnecksquamousc

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Do more moles mean more problems? Not so, says new study

          Thenumberofmolesisnotagoodindicatorofcancer'saggressiveness.APStockDermatologistsconstantlyhammerhom